SLC6A3

Across TCGA pan-cancer cohorts, SLC6A3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC6A3 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SLC6A3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC6A3 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

ESCA, BRCA, and HNSC are the cancer types where SLC6A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.145	0.498	.013	9	view →
BRCA	DFS	Median	III,IV	0.230	0.796	.004	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
UCEC	OS	Median	III,IV	0.962	0.805	.020	6	view →
SKCM	OS	Median	III,IV	0.211	0.729	<.001	6	view →
SCLC	DFS	Median	All	1.000	0.597	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC6A3–ESCA (DFS)

Open the ESCA breakdown →